



ELSEVIER

Contents lists available at ScienceDirect

Carbohydrate Research

journal homepage: www.elsevier.com/locate/carres

C-Glucopyranosyl-1,2,4-triazol-5-ones: synthesis and inhibition of glycogen phosphorylase

Éva Bokor^a, Zsolt Széles^a, Tibor Docsa^b, Pál Gergely^b, László Somsák^{a,*}^a Department of Organic Chemistry, University of Debrecen, POB 20, H-4010 Debrecen, Hungary^b Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, Egyetem tér 1, H-4032 Debrecen, Hungary

ARTICLE INFO

Article history:

Received 8 October 2015

Received in revised form 7 December 2015

Accepted 11 December 2015

Available online

Keywords:

C-glucosyl derivative

1,2,4-Triazol-5-one

Glycogen phosphorylase

Inhibitor

ABSTRACT

Various C-glucopyranosyl-1,2,4-triazolones were designed as potential inhibitors of glycogen phosphorylase. Syntheses of these compounds were performed with O-perbenzoylated glucose derivatives as precursors. High temperature ring closure of *N*'-carbamoyl-C-β-D-glucopyranosyl formamidrazone gave 3-β-D-glucopyranosyl-1,2,4-triazol-5-one. Reaction of *N*'-tosyl-C-β-D-glucopyranosyl formamidrazone with ClCOOEt furnished 3-β-D-glucopyranosyl-1-tosyl-1,2,4-triazol-5-one. In situ prepared β-D-glucopyranosylcarbonyl isocyanate was transformed by PhNHNBoc into 3-β-D-glucopyranosyl-1-phenyl-1,2,4-triazol-5-one, while the analogous 1-(2-naphthyl) derivative was obtained from the unsubstituted triazolone by naphthalene-2-boronic acid in a Cu(II) catalyzed *N*-arylation. Test compounds were prepared by Zemplén deacylation. The new glucose derivatives had weak or no inhibition of rabbit muscle glycogen phosphorylase b: the best inhibitor was 3-β-D-glucopyranosyl-1-(2-naphthyl)-1,2,4-triazol-5-one ($K_i = 80 \mu\text{M}$).

© 2015 Elsevier Ltd. All rights reserved.

1. Introduction

Glycogen phosphorylase (GP) inhibitors (GPIs) may find applications in antidiabetic therapy especially in type 2 diabetes mellitus,¹ but also in other diseases like cerebral^{2,3} and cardiac⁴ ischemias, other cardiovascular impairments,^{4,5} and tumours.^{6,7} A very broad range of compounds with a number of scaffolds was shown to have inhibitory effect against GP⁸ through binding to one (or sometimes more) of the binding sites discovered so far.⁹ The catalytic site of GP can be targeted by glucose derivatives which are competitive inhibitors of the enzyme.^{10,11} Several glucose based GPIs show submicromolar efficiency: the best known inhibitors can be found among glucopyranosylidene-spiro-heterocycles, *N*-acyl-*N*'-β-D-glucopyranosyl ureas, and C-β-D-glucopyranosyl heterocycles. In the latter class of compounds structure-activity relationships have been established for 5-membered heterorings and some of their benzologs (Chart 1). Thus, 2-β-D-glucopyranosyl benzothiazole **1** proved to be a weaker inhibitor in comparison to benzimidazole **2**.¹² This observation could be rationalized by X-ray crystallography of the enzyme-inhibitor complexes showing an H-bond between the imidazole NH and the main chain carbonyl of His377 in the vicinity of the active site of GP.¹³ Extension of **2** by a further aromatic ring as in **3** re-

sulted in an even stronger inhibitor indicating that a large hydrophobic moiety properly protruding into the β-channel^a of the enzyme can be beneficial for the binding.¹⁴ Studies with each possible C-glucosyl oxadiazole isomer revealed that the constitution of the heterocycles was also an important factor and 5-β-D-glucopyranosyl-3-substituted-1,2,4-oxadiazoles **4** and **7** proved to be the best inhibitors of these series.^{15,16} Changing the oxadiazole to 1,2,4-triazole furnished inhibitors **5** and **8** exhibiting stronger binding most probably due to the H-bonding capacity of the triazoles,^{17,18} and imidazoles **6** and **9** were shown to be even better inhibitors.¹⁹ Although no structural data have yet been available to rationalize this finding, one may speculate that the stronger inhibition of imidazoles can be a result of the smaller number of ring tautomers in comparison to the case of triazoles. Tautomeric forms have recently been shown to have a very important contribution to the determination of the binding strength of GP inhibitors.²⁰ The observation that the naphthyl substituted compounds **7-9** bind stronger to the enzyme than the phenyl substituted **4-6** corroborates the role of the large hydrophobic group. Based on the above considerations, we have designed 3-C-glucopyranosyl-1-substituted-1,2,4-triazol-5-ones as further candidates of potential GPIs in which the presence of the carbonyl group might result in decreasing the number of tautomers due to the stability of the NHCO moiety.

* Corresponding author. Department of Organic Chemistry, University of Debrecen, POB 20, H-4010 Debrecen, Hungary. Tel.: +36 52512900 ext 22348; fax: +36 52512744.

E-mail address: somsak@tigris.unideb.hu (L. Somsák).

^a The β-channel is an empty space next to the catalytic site of GP in the direction of the β-anomeric substituent of bound D-glucose surrounded by both polar and apolar amino acid side chains.





Chart 1. Inhibitory potency (K_i [μM]) of selected C- β -D-glucopyranosyl heterocycles against rabbit muscle glycogen phosphorylase *b* (RMGPb).

2. Results and discussion

Several methods were reported for the syntheses of various 1,2,4-triazol-5-ones,²¹ e.g. starting with nitriles,^{22,23} imidates,²⁴ N^1 -acyl-semicarbazides,²⁵ N^1 -tosyl-amidrazones,²⁶ or aldehyde-semicarbazones.²⁷ C-Glycosyl-1,2,4-triazol-5-ones could not be located in the literature. The only related work found was that of Poonian and Nowoswiat²⁸ reporting the transformation of β -D-ribofuranosyl formimidate by (thio)semicarbazide to the corresponding C- β -D-ribofuranosyl- N^1 -(thio)carbamoyl formamidrazones. While the ring closure of the thiocarbamoyl de-

Table 1
Synthesis of *O*-perbenzoylated N^1 -substituted C- β -D-glucopyranosyl formamidrazones


Reagent	R	Product	Conditions	Yield (%)
11		14	<i>a</i>	55
12		15	<i>b</i>	80
13		16	<i>a</i>	83



Scheme 1. Reagents and conditions: *a*) dry *m*-xylene, reflux; *b*) dry DMF, reflux; *c*) ClCOEt, dry CHCl_3 , dry pyridine, 0 °C to rt; *d*) cat. NaOMe in dry MeOH, rt.

rivative to a 1,2,4-triazol-5-thione could be achieved at elevated temperature, similar attempts to get the corresponding 1,2,4-triazol-5-one failed.²⁸

Since from earlier work we had in hand the *O*-perbenzoylated β -D-glucopyranosyl formimidate¹⁴ (**10**, Table 1), this compound was used as the starting material for the preparation of some new amidrazones suitable for ring closure towards the expected 1,2,4-triazol-5-ones. Reactions of **10** with ethyl carbazate (**11**), semicarbazide (**12**) or 2,4-dinitrophenylhydrazine (**13**) smoothly gave the corresponding C-glucosyl formamidrazones **14–16**, respectively. Boiling a solution of **14** in *m*-xylene brought about the expected ring closure; however, the reaction was accompanied by a 1,2-elimination of benzoic acid resulting in glucal **18** in low yield (Scheme 1). Cyclization of N^1 -carbamoyl-amidrazone **15** in boiling DMF took place without concomitant elimination producing the expected triazolone **19** in good yield. Subsequent *O*-debenzoylation under Zemplén conditions gave test compound **20**. Attempted cyclization of **16** with ClCOEt in CHCl_3 in the presence of 2 equiv. of pyridine or DIPEA at r. t. or with boiling failed; actually, no reaction could be observed. Reaction²⁶ of tosyl-amidrazone **17**^{17,29} with ClCOEt produced the tosylated triazolone **21** which was deprotected according to the Zemplén protocol to give the test compound **22**.



Scheme 2. Reagents and conditions: a) $(\text{COCl})_2$, dry 1,2-dichloroethane, reflux; b) dry THF, 0°C to rt; c) dry *m*-xylene, reflux; d) CF_3COOH , dry CH_2Cl_2 , rt; e) cat. NaOMe in dry MeOH, rt.

Next we wished to prepare isomers of *N*-phenyl substituted triazolones. To obtain 5- β -D-glucopyranosyl-1-phenyl-1,2,4-triazol-3-one, compound **25** was prepared as the starting material (Scheme 2). C-Glucosyl formamide **23**^{30,31} was converted by oxalyl chloride³² into the acyl isocyanate **24** which was used without purification for the next reaction with PhNHNH_2 to give **25** in very good yield. Towards 3- β -D-glucopyranosyl-1-phenyl-1,2,4-triazol-5-one, intermediate **24** was reacted with Boc-protected PhNHNH_2 to give **26**. Treatment of **26** by CF_3COOH , in analogy with a reported procedure,³³ cleaved the protecting group and spontaneous ring closure gave the expected triazolone **27**. To our surprise, this compound proved identical with that obtained by heating **25** in *m*-xylene; however, this unexpected outcome had a precedent in the literature.³⁴ Besides the chemical evidence of the route **26**→**27**, spectroscopic verification for the structure of **27** was also sought for. To this end, a 2D ^1H - ^1H ROESY spectrum was recorded which showed the vicinity of the triazolone NH to H1 and H2 of the sugar moiety, thereby indicating the position of the aromatic residue (Fig. 1; for the spectra see Supporting information). Deprotection of **27** under Zemplén conditions furnished test compound **28** in excellent yield.

In order to have a triazolone with a larger aromatic substituent, synthesis of the 2-naphthyl derivative was envisaged. Although a synthetic sequence analogous to **23**→**24**→**26**→**27** seemed straightforward, the unavailability of the necessary 2-naphthyl-hydrazine prevented the application of this route. Therefore, a copper catalyzed cross-coupling protocol for the *N*-arylation of amides was adapted.³⁵ The reaction of triazolone **19** with naphthalene-2-boronic acid in the presence of $\text{Cu}(\text{OAc})_2$ and Et_3N gave low yield of **29** (Scheme 3). The structure of this product was considered to be analogous to that of **27** based on the coincidences of the chemical shifts both in the ^1H and ^{13}C NMR spectra of **27** and **29**. In

addition, the structure was also corroborated by a 2D ^1H - ^1H ROESY experiment (Fig. 1; for the spectra, see Supporting information). Zemplén deprotection of **29** produced test compound **30** in good yield.

The new compounds were assayed against rabbit muscle glycogen phosphorylase b (RMGPb) as described previously³⁶ (Table 2). The unsubstituted triazolone **20** and its 1-tosylated derivative **22** had no significant effect. In the case of **20**, the inefficiency may be explained by the relatively small size of the aglycon which cannot interact in the β -channel of the enzyme. This resembles the case of the similarly non inhibitory 5- β -D-glucopyranosyl tetrazole.¹² For **22**, where the tosyl substituent can occupy the β -channel, the lack of efficiency may be attributed to the presence of the SO_2 moiety. Such a tetrahedral linking element in the aglycon was shown to be detrimental to the binding in some types of glucose derived compounds.^{8,11,38–40} The 1-aryl-substituted triazolones **28** and **30** had weak inhibitory effects whereby the 2-naphthyl derivative **30** showed stronger binding than the phenyl compound **28**. This reflects the general trend regarding the size and orientation of aryl substituents that were observed in many cases (cf examples **4–6** vs **7–9** in Chart 1). On the other hand, the triazolone ring between the sugar









Fig. 1. Nuclear Overhauser effects in 1-aryl-3- β -D-glucopyranosyl-1,2,4-triazol-5-ones (**27** (Ar = Ph) and **29** (Ar = 2-naphthyl)).



Scheme 3. Reagents and conditions: a) $\text{Cu}(\text{OAc})_2$, Et_3N , CH_2Cl_2 , rt; b) cat. NaOMe in dry MeOH, rt.

Table 2
Inhibition of RMGPb by C-glucopyranosyl-1,2,4-triazol-5-ones

Compound	Inhibition [μM]
	No inhibition at 625 μM
20	
	No inhibition at 625 μM
22	
	IC_{50} 350 K_i 191 ^a
28	
	K_i 80
30	

^a Calculated from the IC_{50} by a web-based tool.³⁷

and the aromatic part must have insufficient interactions with the amino acid side chains of RMGPb, resulting in weaker inhibition than many of other 5-membered C-glucosyl heterocycles studied so far.

In conclusion, synthetic methods have been elaborated to obtain hitherto unknown 3- β -D-glucopyranosyl-1-(un)substituted-1,2,4-triazol-5-ones. Enzyme kinetic tests with rabbit muscle glycogen phosphorylase b revealed 1-aryl-triazolones to be weak inhibitors, thereby contributing to structure–activity relationships of C-glucosyl heterocycles.

3. Experimental

3.1. General methods

Melting points were measured on a Kofler hot-stage and are uncorrected. Optical rotations were determined with a Perkin-Elmer 241 polarimeter at rt. NMR spectra were recorded with Bruker 360 (360/90 MHz for $^1\text{H}/^{13}\text{C}$) or Bruker 400 (400/100 MHz for $^1\text{H}/^{13}\text{C}$) spectrometers. 2D ^1H - ^1H ROESY (400 MHz) spectra were acquired with 150 ms spinlock for mixing in overnight experiments. Chemical shifts are referenced to Me_4Si (^1H), or to the residual solvent signals (^{13}C). Mass spectra were obtained by Thermo Scientific LTQ XL or MicroTOF-Q type Qq-TOF MS (Bruker Daltonik, Bremen, Germany) instruments. TLC was performed on DC-Alurolle Kieselgel 60 F₂₅₄ (Merck) plates, visualized under UV light and by gentle heating. For column chromatography, Kieselgel 60 (Merck, particle size 0.063–0.200 mm) was used. Toluene, *m*-xylene, CH_2Cl_2 , CHCl_3 were distilled from P_4O_{10} and stored over 4 Å molecular sieves or sodium wires. MeOH was purified by distillation after refluxing for a couple of hours with magnesium turnings and iodine. THF was distilled from sodium benzophenone ketyl and stored over sodium wires. Anhydrous solvents: EtOH (Sigma-Aldrich), DMF (Sigma-Aldrich), 1,2-dichloroethane (Sigma-Aldrich) and pyridine (VWR) were purchased from the indicated companies. Ethyl C-(2,3,4,6-tetra-O-benzoyl- β -D-glucopyranosyl)formimidate¹⁴ (**10**), *N*¹-tosyl-C-(2,3,4,6-tetra-O-benzoyl- β -D-glucopyranosyl)formamidrazone¹⁷ (**17**), C-(2,3,4,6-tetra-O-benzoyl- β -D-glucopyranosyl)formamide³⁰ (**23**) and PhNHNHoc⁴¹ were synthesized according to published procedures.

3.2. General procedure for removal of benzoyl protecting groups by the Zemplén protocol

To a solution of an *O*-perbenzoylated compound in anhydrous MeOH (5 mL/100 mg, a few drops of anhydrous CHCl_3 were added in case of incomplete dissolution), a catalytic amount of a NaOMe solution (1 M in MeOH) was added and the mixture was left at rt. After completion of the reaction monitored by TLC (1:1 EtOAc-hexane and 7:3 CHCl_3 -MeOH), the mixture was neutralized with a cation exchange resin Amberlyst 15 (H^+ form), then the resin was filtered off and the solvent was removed. The crude product was purified by column chromatography.

3.3. *N*¹-Ethoxycarbonyl-C-(2,3,4,6-tetra-O-benzoyl- β -D-glucopyranosyl)formamidrazone (**14**)

Ethyl

C-(2,3,4,6-tetra-O-benzoyl- β -D-glucopyranosyl)formimidate¹⁴ (**10**, 1.00 g, 1.53 mmol) and ethyl carbazate (**11**, 0.16 g 1.53 mmol) were stirred in anhydrous EtOH (20 mL) at reflux temperature, and the reaction was monitored by TLC (1:1 EtOAc-hexane). After completion of the reaction (5 h), the mixture was evaporated under diminished pressure, and the crude product was purified by column chromatography (1:1 EtOAc-hexane) to yield 0.60 g (55%) white solid. Mp: 104–106 °C; $[\alpha]_{\text{D}} = -21$ (c 0.55, CHCl_3); ^1H NMR (CDCl_3) δ (ppm): 8.61 (1H, br s, NH), 8.04–7.82 (8H, m, Ar), 7.57–7.25 (12H, m, Ar), 5.99, 5.74, 5.63 (3 \times 1H, 3 pseudo t, $J = 9.6$, 9.6 Hz in each, H-2, H-3, H-4), 5.15 (2H, br s, NH_2), 4.63 (1H, dd, $J = 12.3$, < 1 Hz, H-6a), 4.52 (1H, dd, $J = 12.3$, 5.3 Hz, H-6b), 4.46 (1H, d, $J = 9.6$ Hz, H-1), 4.25 (1H, ddd, $J = 9.6$, 5.3, < 1 Hz, H-5) 3.94 (2H, q, $J = 7.0$ Hz, CH_2), 1.00 (3H, t, $J = 7.0$ Hz, CH_3); ^{13}C NMR (CDCl_3) δ (ppm): 166.0, 165.5 (2), 165.1 (C=O), 155.5 (COEt), 146.9 (C=N), 133.3–128.1 (Ar), 77.4, 76.0, 73.6, 70.4, 69.2 (C-1 – C-5), 63.0, 61.4 (C-6, CH_2), 14.1 (CH_3). MS-ESI (m/z): Calcd. for $\text{C}_{38}\text{H}_{35}\text{N}_3\text{NaO}_{11}^+$ [$\text{M} + \text{Na}$]⁺: 732.216. Found: 732.216.

3.4. *N*¹-Carbamoyl-C-(2,3,4,6-tetra-O-benzoyl- β -D-glucopyranosyl)formamidrazone (**15**)

Ethyl

C-(2,3,4,6-tetra-O-benzoyl- β -D-glucopyranosyl)formimidate¹⁴ (**10**, 0.10 g, 0.15 mmol) and semicarbazide hydrochloride (**12**, 0.03 g, 0.31 mmol) were stirred in anhydrous pyridine (3 mL) at rt. After disappearance of the imidate (3 h) monitored by TLC (EtOAc), the pyridine was removed under diminished pressure and the residue was purified by column chromatography (EtOAc) to give 0.08 g (80%) white solid. Mp: 131–133 °C; $[\alpha]_{\text{D}} = +36$ (c 0.50, CHCl_3); ^1H NMR (CDCl_3) δ (ppm): 9.57 (1H, s, NH), δ (ppm): 8.02–7.82 (4 \times 2H, 4 d, $J = 7.3$ Hz, Ar), 7.55–7.24 (12H, m, Ar), 5.94, 5.83, 5.68 (3 \times 1H, 3 pseudo t, $J = 9.2$, 9.2 Hz in each, H-2, H-3, H-4), 5.25 (2H, s, NH_2), 4.63 (1H, dd, $J = 12.6$, 2.6 Hz, H-6a), 4.46 (1H, dd, $J = 12.6$, 5.3 Hz, H-6b), 4.29 (1H, d, $J = 9.2$ Hz, H-1), 4.19 (1H, ddd, $J = 9.2$, 5.3, 2.6 Hz, H-5); ^{13}C NMR (CDCl_3) δ (ppm): 166.1, 165.8, 165.5, 165.1 (C=O), 159.0 (C=ONH₂), 141.5 (C=N), 133.4–133.1, 129.7–128.2 (Ar), 77.2, 76.1, 74.0, 69.7, 69.2 (C-1 – C-5), 63.0 (C-6). MS-ESI (m/z): Calcd. for $\text{C}_{36}\text{H}_{33}\text{N}_4\text{O}_{10}^+$ [$\text{M} + \text{H}$]⁺: 681.2. Found: 681.7.

3.5. *N*¹-(2,4-Dinitrophenyl)-C-(2,3,4,6-tetra-O-benzoyl- β -D-glucopyranosyl)formamidrazone (**16**)

Ethyl

C-(2,3,4,6-tetra-O-benzoyl- β -D-glucopyranosyl)formimidate¹⁴ (**10**, 0.10 g, 0.15 mmol) and 2,4-dinitrophenylhydrazine (**13**, 61 mg, 0.31 mmol) were refluxed in anhydrous EtOH (3 mL), and the reaction was monitored by TLC (2:3 EtOAc-hexane). After total consumption of the imidate (1 d), the solvent was removed and the

residue was purified by column chromatography (3:7 EtOAc-hexane) to give 0.10 g (83%) red syrup. R_f : 0.50 (2:3 EtOAc-hexane); $[\alpha]_D = -66$ (c 0.30, CHCl₃); ¹H NMR (CDCl₃) δ (ppm): 10.16 (1H, s, NH), 8.89 (1H, d, $J = 2.6$ Hz, Ar), 8.04–7.84 (4 × 2H, 4 dd, $J = 7.3$, 1.0 Hz in each, Ar), 7.62 (1H, dd, $J = 9.6$, 2.6 Hz, Ar), 7.54–7.24 (12H, m, Ar), 7.05 (1H, d, $J = 9.6$ Hz, Ar), 6.11, 5.82, 5.77 (3 × 1H, 3 pseudo t, $J = 9.6$, 9.6 Hz in each, H-2, H-3, H-4), 5.31 (2H, br s, NH₂), 4.75 (1H, dd, $J = 12.6$, 2.6 Hz, H-6a), 4.58 (1H, dd, $J = 12.6$, 5.3 Hz, H-6b), 4.54 (1H, d, $J = 9.6$ Hz, H-1), 4.36 (1H, ddd, $J = 9.6$, 5.3, 2.6 Hz, H-5); ¹³C NMR (CDCl₃) δ (ppm): 166.3, 165.8, 165.3 (2) (C=O), 150.1, 145.3 (C=N, DNP-C-1), 137.0 (DNP-C-4), 133.7–133.4, 129.9–128.4 (Ar), 123.2, 116.0 (DNP-C-3, DNP-C-6) 77.0, 76.6, 73.4, 70.5, 69.1 (C-1 – C-5), 63.0 (C-6). MS-ESI (m/z): Calcd. for C₄₁H₃₄N₅O₁₃⁺ [M + H]⁺: 804.2. Found: 804.5.

3.6. 3-(3',4',6'-Tri-O-benzoyl-2'-deoxy-D-arabino-hex-1'-enopyranosyl)-1H-1,2,4-triazol-5(4H)-one (18)

The solution of amidrazone **14** (0.40 g, 0.56 mmol) in anhydrous *m*-xylene (8 mL) was heated at 140 °C, and the reaction was monitored by TLC (4:1 EtOAc-hexane). After total consumption of the starting material (2 h) the solvent was removed, and the residue was purified by column chromatography (7:2 EtOAc-hexane) to yield 0.11 g (37%) pale yellow solid. Mp: 205–207 °C; $[\alpha]_D = +13$ (c 0.51, DMSO); ¹H NMR (DMSO-*d*₆) δ (ppm): 11.92, 11.83 (2 × 1H, 2 s, NH), 7.97–7.93 (6H, m, Ar), 7.67–7.64 (3H, m, Ar), 7.54–7.48 (6H, m, Ar), 5.91 (1H, dd, $J = 5.5$, 3.7 Hz, H-3'), 5.83 (1H, d, $J = 3.7$ Hz, H-2'), 5.80 (1H, dd, $J = 6.8$, 5.5 Hz, H-4'), 5.06 (1H, ddd, $J = 6.8$, 5.5, 3.1 Hz, H-5'), 4.77 (1H, dd, $J = 12.3$, 5.5 Hz, H-6'a), 4.66 (1H, dd, $J = 12.3$, 3.1 Hz, H-6'b); ¹³C NMR (DMSO-*d*₆) δ (ppm): 165.3, 165.0, 164.5 (C=O), 155.5 (triazolone C=O), 143.1, 140.4 (C-1', triazolone C-3), 133.8, 133.7, 133.5, 129.4–128.7 (Ar), 98.1 (C-2'), 74.1, 67.8, 67.0 (C-3' – C-5'), 61.4 (C-6'). MS-ESI (m/z): Calcd. for C₂₉H₂₄N₃O₈⁺ [M + H]⁺: 542.2. Found: 542.3.

3.7. 3-(2',3',4',6'-Tetra-O-benzoyl-β-D-glucopyranosyl)-1H-1,2,4-triazol-5(4H)-one (19)

The amidrazone **15** (2.0 g, 2.94 mmol) was refluxed in anhydrous DMF (50 mL), and the reaction was monitored by TLC (EtOAc). After disappearance of the starting material (2 h), the solvent was removed under reduced pressure, and the residue was purified by column chromatography (EtOAc) to yield 1.35 g (69%) white solid. Mp: 281–283 °C; $[\alpha]_D = -13$ (c 0.47, DMSO); ¹H NMR (DMSO-*d*₆) δ (ppm): 11.91, 11.46 (2 × 1H, 2 s, NH), 8.04–7.36 (20H, m, Ar), 6.15, 5.82, 5.69 (3 × 1H, 3 pseudo t, $J = 9.2$, 9.2 Hz in each, H-2', H-3', H-4'), 5.10 (1H, d, $J = 9.2$ Hz, H-1'), 4.67 (1H, ddd, $J = 9.2$, 5.3, < 1 Hz, H-5'), 4.53 (2H, s, H-6'a, H-6'b); ¹³C NMR (DMSO-*d*₆) δ (ppm): 165.3, 165.1, 164.7, 164.3 (C=O), 155.8 (triazolone C=O), 143.3 (triazolone C-3), 133.8–133.4, 129.4–128.3 (Ar), 74.5, 73.8, 71.6, 70.1, 68.6 (C-1' – C-5'), 62.3 (C-6'). MS-ESI (m/z): Calcd. for C₃₆H₃₀N₃O₁₀⁺ [M + H]⁺: 664.2. Found: 664.3.

3.8. 3-(β-D-Glucopyranosyl)-1H-1,2,4-triazol-5(4H)-one (20)

Prepared from compound **19** (0.27 g, 0.41 mmol) according to the general procedure (Section 3.2.). Reaction time: 1 d. Purified by column chromatography (5:4 CHCl₃-MeOH) to yield 60 mg (60%) colourless syrup. $R_f = 0.32$ (1:1 CHCl₃-MeOH), $[\alpha]_D = +9$ (c 0.10, MeOH); ¹H NMR (DMSO-*d*₆ + 1 drop D₂O) δ (ppm): 4.70 (1H, d, $J = 9.9$ Hz, H-1'), 4.46 (1H, dd, $J = 11.9$, 2.6 Hz, H-6'a), 4.25–4.18 (2H, m, H-2' or H-3' or H-4', H-6'b), 4.06–4.00 (2H, m, H-2' or H-3' or H-4', H-5'), 3.93 (1H, pseudo t, $J = 9.9$, 9.2 Hz, H-2' or H-3' or H-4'); ¹³C NMR (DMSO-*d*₆) δ (ppm): 156.1 (triazolone C=O), 145.7 (triazolone C-3), 81.3, 77.7, 74.7, 71.0, 69.8 (C-1' – C-5'), 61.1 (C-6'). MS-ESI (m/z): Calcd. for C₈H₁₄N₃O₆⁺ [M + H]⁺: 248.1; C₈H₁₃N₃NaO₆⁺

[M + Na]⁺: 270.1. Found: [M + H]⁺: 248.2; [M + Na]⁺: 270.5. Anal: Calcd for C₈H₁₃N₃O₆ (M 247.205): C, 38.87; H, 5.30; N, 17.00. Found: C, 39.09; H, 5.43; N, 16.89.

3.9. 3-(2',3',4',6'-Tetra-O-benzoyl-β-D-glucopyranosyl)-1-tosyl-1H-1,2,4-triazol-5(4H)-one (21)

To a solution of amidrazone¹⁷ **17** (0.20 g, 0.25 mmol) in anhydrous CHCl₃ (3 mL) anhydrous pyridine (37 μL, 0.45 mmol, 1.8 equiv.) was added. The mixture was then cooled in an ice bath, and a solution of ethyl chloroformate (36 μL, 0.38 mmol, 1.5 ekv.) in anhydrous CHCl₃ (3 mL) was added dropwise over 15 minutes. The mixture was then stirred at rt, and the reaction was monitored by TLC (2:3 EtOAc-hexane). After 1 week, the mixture was concentrated under diminished pressure, and the crude product was purified by column chromatography (1:2 EtOAc-hexane) to give 0.14 g (70%) white solid. Mp: 105–107 °C; $[\alpha]_D = +6$ (c 0.56, CHCl₃); ¹H NMR (CDCl₃) δ (ppm): 10.89 (1H, br s, NH), 8.06–7.16 (22H, m, Ar), 7.02 (2H, d, $J = 7.4$ Hz, Ar), 6.01 (1H, pseudo t, $J = 9.2$, 9.2 Hz, H-2' or H-3' or H-4'), 5.84–5.78 (2H, m, H-2' and/or H-3' and/or H-4'), 4.86 (1H, d, $J = 9.2$ Hz, H-1'), 4.63 (1H, dd, $J = 12.3$, < 1 Hz, H-6'a), 4.50 (1H, dd, $J = 12.3$, 4.9 Hz, H-6'b), 4.32 (1H, ddd, $J = 9.2$, 4.9, < 1 Hz, H-5'), 2.26 (3H, s, CH₃); ¹³C NMR (CDCl₃) δ (ppm): 166.2, 165.6, 165.1, 164.8 (C=O), 151.9 (triazolone C=O), 145.6, 145.0 (triazolone C-3, Ts-C-1 or Ts-C-4), 133.7 (Ts-C-1 or Ts-C-4), 133.4–133.1, 130.0–127.9 (Ar), 76.6, 73.5, 72.6, 69.8, 69.0 (C-1' – C-5'), 63.0 (C-6'), 21.5 (CH₃). MS-ESI (m/z): Calcd. for C₄₃H₃₆N₃O₁₂S⁺ [M + H]⁺: 818.2. Found: 818.5.

3.10. 3-(β-D-Glucopyranosyl)-1-tosyl-1H-1,2,4-triazol-5(4H)-one (22)

Prepared from compound **21** (0.20 g, 0.24 mmol) according to the general procedure (Section 3.2.). Reaction time: 7 h. Purified by column chromatography (9:1 CHCl₃-MeOH) to yield 55 mg (56%) colourless syrup. $R_f = 0.54$ (7:3 CHCl₃-MeOH), $[\alpha]_D = -7$ (c 0.31, MeOH); ¹H NMR (DMSO-*d*₆) δ (ppm): 12.34 (1H, br s, NH), 7.84, 7.48 (2 × 2H, 2 d, $J = 7.9$ Hz in each, Ar), 5.24, 5.14, 5.02, 4.46 (4 × 1H, OH), 3.89 (1H, d, $J = 9.2$ Hz, H-1'), 3.64 (1H, dd, $J = 11.9$, 2.6 Hz, H-6'a), 3.22–3.07 (5H, m, H-2', H-3', H-4', H-5', H-6'b), 2.41 (3H, s, CH₃); ¹³C NMR (CD₃OD) δ (ppm): 154.4, 150.6, 147.7 (triazolone C=O, triazolone C-3, Ts-C-1 or Ts-C-4), 135.7, 131.2 (2), 129.1 (2) (Ar), 82.2, 78.9, 76.0, 73.0, 70.9 (C-1' – C-5'), 62.4 (C-6'), 21.7 (CH₃). MS-ESI (m/z): Calcd. for C₁₅H₂₀N₃O₈S⁺ [M + H]⁺: 402.1. Found: 402.3. Anal: Calcd for C₁₅H₁₉N₃O₈S (M 401.39): C, 44.88; H, 4.77; N, 10.47. Found: C, 45.16; H, 4.85; N, 10.42.

3.11. N¹-Phenyl-N⁴-(2',3',4',6'-tetra-O-benzoyl-β-D-glucopyranosylcarbonyl)semicarbazide (25)

To a solution of C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)formamide³⁰ (**23**, 2.5 g, 4.0 mmol) in anhydrous 1,2-dichloroethane (50 mL) oxalyl chloride (0.68 mL, 8.0 mmol) was added, and the mixture was refluxed for 1 d. The reaction mixture was then concentrated under diminished pressure, and traces of oxalyl chloride was removed by repeated co-evaporations with toluene. The remaining syrup was dissolved in anhydrous THF (50 mL), the solution was cooled to 0 °C and phenylhydrazine (0.6 mL, 6.0 mmol) was added. Subsequently the reaction mixture was allowed to warm to rt and stirred for 1 d. The solvent was then removed under reduced pressure, and the residue was crystallized from diethyl ether to give 2.1 g (69% for two steps) pale yellow solid. Mp: 219–221; $[\alpha]_D = -17$ (c 0.51, CHCl₃); ¹H NMR (CDCl₃) δ (ppm): 9.53, 9.47 (2 × 1H, 2 s, NH), 8.03–6.86 (25H, m, Ar), 6.21 (1H, s, NH), 5.89 (1H, pseudo t, $J = 9.0$, 8.5 Hz, H-2' or H-3' or H-4'), 5.75–5.64 (2H, m, H-2' and/or H-3' and/or H-4'), 4.64 (1H, dd, $J = 11.5$, < 1 Hz, H-6'a), 4.42 (1H, dd, $J = 11.5$, 3.4 Hz, H-6'b), 4.15 (1H, d, $J = 9.3$ Hz, H-1'), 4.09 (1H, m, H-5'); ¹³C

NMR (CDCl₃) δ (ppm): 168.0, 166.4, 165.7, 165.1 (2), 154.1 (C=O), 147.6, 133.6–133.2, 129.8–128.3, 121.0, 113.1 (Ar), 76.4, 76.2, 73.2, 69.4, 69.0 (C-1' – C-5'), 63.0 (C-6'). MS-ESI (*m/z*): Calcd. for C₄₂H₃₆N₃O₁₁⁺ [M + H]⁺: 758.2. Found: 758.5.

3.12. N¹-(tert-Butoxycarbonyl)-N²-phenyl-N⁴-(2',3',4',6'-tetra-O-benzoyl-β-D-glucopyranosylcarbonyl)semicarbazide (26)

To a solution of C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)formamide³⁰ (**23**, 0.5 g, 0.80 mmol) in anhydrous 1,2-dichloroethane (12 mL) oxalyl chloride (136 μL, 0.16 mmol) was added, and the mixture was heated at reflux temperature for 1 d. The reaction mixture was then concentrated under diminished pressure, and traces of oxalyl chloride was removed by repeated co-evaporations with toluene. The remaining syrup was dissolved in anhydrous THF (10 mL), the solution was cooled to 0 °C and PhNHNHoc (0.25 g, 1.2 mmol) was added. Subsequently, the reaction mixture was allowed to warm to rt and stirred for 3 h. The solvent was then evaporated under reduced pressure and the residue was purified by column chromatography (1:2 EtOAc-hexane) to obtain the title compound **26** (0.35 g) as the first than amide **23** (0.12 g) as the second fraction. Yield of the title compound for two steps: 66% (corrected with the recovered starting material **23**). Mp: 192–194 °C (white solid); [α]_D = -7 (c 0.21, CHCl₃); ¹H NMR (DMSO-d₆) δ (ppm): 10.03, 9.86 (2 × 1H, 2 br s, NH), 7.98–7.17 (25H, m, Ar), 6.03, 5.80, 5.68 (3 × 1H, 3 pseudo t, *J* = 9.4, 9.4 Hz in each, H-2', H-3', H-4'), 4.91 (1H, d, *J* = 9.4 Hz, H-1'), 4.57–4.41 (3H, m, H-5', H-6'a, H-6'b), 1.34 (9H, s, C(CH₃)₃); ¹³C NMR (DMSO-d₆) δ (ppm): 165.3 (2), 165.1, 164.6, 164.4, 154.5, 150.3 (C=O), 141.0, 133.7–133.4, 129.2–128.4, 124.0 (Ar), 80.6 (C(CH₃)₃), 75.5, 74.6, 74.0, 69.4, 68.6 (C-1' – C-5'), 62.8 (C-6'), 27.7 (C(CH₃)₃). MS-ESI (*m/z*): Calcd. for C₄₇H₄₄N₃O₁₃⁺ [M + H]⁺: 858.3. Found: 858.1.

3.13. 1-Phenyl-3-(2',3',4',6'-tetra-O-benzoyl-β-D-glucopyranosyl)-1H-1,2,4-triazol-5(4H)-one (27)

A: The solution of compound **25** (1.0 g, 1.32 mmol) in anhydrous *m*-xylene (40 mL) was heated at boiling temperature, and the reaction was monitored by TLC (1:1 EtOAc-hexane). After total consumption of the starting material (1 d), the solvent was removed, and the residue was purified by column chromatography (1:2 EtOAc-hexane) to give 0.36 g (37%) colourless syrup. **B:** To a solution of compound **26** (0.23 g, 0.27 mmol) in anhydrous CH₂Cl₂ (10 mL) trifluoroacetic acid (124 μL, 1.61 mmol) was added and the mixture was stirred at rt. After disappearance of the starting material (4 d) monitored by TLC (2:3 EtOAc-hexane), the solvent was removed under diminished pressure, and the residue was purified by column chromatography (1:2 EtOAc-hexane) to yield 0.17 g (87%) colourless syrup. *R*_f: 0.54 (1:1 EtOAc-hexane); [α]_D = +16 (c 0.61, CHCl₃); ¹H NMR (CDCl₃) δ (ppm): 11.58 (1H, br s, NH), 8.00–7.83 (4 × 2H, 4 d, *J* = 7.0 Hz in each, Ar), 7.67 (2H, d, *J* = 7.8 Hz, Ar), 7.52–7.10 (15H, m, Ar), 6.06, 5.91, 5.80 (3 × 1H, 3 pseudo t, *J* = 9.4, 9.4 Hz in each, H-2', H-3', H-4'), 4.90 (1H, d, *J* = 9.4 Hz, H-1'), 4.69 (1H, dd, *J* = 12.5, 3.1 Hz, H-6'a), 4.57 (1H, dd, *J* = 12.5, 5.5 Hz, H-6'b), 4.35 (1H, ddd, *J* = 9.4, 5.5, 3.1 Hz, H-5'); ¹³C NMR (CDCl₃) δ (ppm): 166.2, 165.8, 165.1, 165.0 (C=O), 153.4 (triazolone C=O), 142.6 (triazolone C-3), 137.3, 133.5–133.1, 129.9–128.3, 125.5, 118.7 (Ar), 76.8, 73.5, 72.7, 70.2, 69.2 (C-1' – C-5'), 63.1 (C-6'). ESI-MS positive mode (*m/z*): calcd for C₄₂H₃₄N₃O₁₀⁺ [M + H]⁺: 740.2. Found: 740.4.

3.14. 3-(β-D-Glucopyranosyl)-1-phenyl-1H-1,2,4-triazol-5(4H)-one (28)

Prepared from compound **27** (0.23 g, 0.31 mmol) according to the general procedure (Section 3.2). Reaction time: 6 h. Purified by

column chromatography (85:15 CHCl₃-MeOH) to yield 94 mg (95%) white solid. Mp: 238–240 °C [α]_D = +30 (c 0.40, MeOH); ¹H NMR (DMSO-d₆ + 1 drop D₂O) δ (ppm): 7.83 (2H, d, *J* = 7.8 Hz, Ar), 7.43 (2H, pseudo t, *J* = 7.8 Hz, Ar), 7.21 (1H, t, *J* = 7.8 Hz, Ar), 4.04 (1H, d, *J* = 9.4 Hz, H-1'), 3.69 (1H, dd, *J* = 11.7, 5.5 Hz, H-6'a), 3.46 (1H, pseudo t, *J* = 9.4, 9.4 Hz, H-2' or H-3' or H-4'), 3.44 (1H, dd, *J* = 11.7, 3.1 Hz, H-6'b), 3.30–3.25 (2H, m, H-2' or H-3' or H-4', H-5'), 3.16 (1H, pseudo t, *J* = 9.4, 9.4 Hz, H-2' or H-3' or H-4'); ¹³C NMR (DMSO-d₆) δ (ppm): 152.6 (triazolone C=O), 145.7 (triazolone C-3), 137.7, 129.0 (2), 124.7, 117.9, 117.7 (Ar), 81.4, 77.5, 74.5, 71.1, 69.8 (C-1' – C-5'), 61.1 (C-6'). MS-ESI (*m/z*): Calcd. for C₁₄H₁₈N₃O₆⁺ [M + H]⁺: 324.1. Found: 324.2. Anal: Calcd for C₁₄H₁₇N₃O₆ (M 323.30): C, 52.01; H, 5.30; N, 13.00. Found: C, 52.09; H, 5.46; N, 12.85.

3.15. 1-(2-Naphthyl)-3-(2',3',4',6'-tetra-O-benzoyl-β-D-glucopyranosyl)-1H-1,2,4-triazol-5(4H)-one (29)

To a solution of compound **19** (0.10 g, 0.15 mmol) in anhydrous CH₂Cl₂ (3 mL) 2-naphthylboronic acid (52 mg, 0.30 mmol), Cu(OAc)₂ (27 mg, 0.15 mmol) and Et₃N (42 μL, 0.30 mmol) were added, and the reaction mixture was stirred at rt. When the TLC (1:1 EtOAc-hexane) showed total consumption of **20** (1 d), the solvent was evaporated. The residue was purified by column chromatography (2:3 EtOAc-hexane) to give 24 mg (20%) pale yellow amorphous solid. *R*_f: 0.51 (1:1 EtOAc-hexane); [α]_D = +11 (c 0.44, CHCl₃); ¹H NMR (CDCl₃) δ (ppm): 11.89 (1H, br s, NH), 8.12 (1H, s, Ar), 7.97–7.20 (26H, m, Ar), 6.10, 5.98, 5.84 (3 × 1H, 3 pseudo t, *J* = 9.2, 9.2 Hz in each, H-2', H-3', H-4'), 4.95 (1H, d, *J* = 9.2 Hz, H-1'), 4.72 (1H, dd, *J* = 11.9, 2.6 Hz, H-6'a), 4.61 (1H, dd, *J* = 11.9, 5.3 Hz, H-6'b), 4.37 (1H, ddd, *J* = 9.2, 5.3, 2.6 Hz, H-5'); ¹³C NMR (CDCl₃) δ (ppm): 166.2, 165.8, 165.1 (2) (C=O), 153.7 (triazolone C=O), 142.9 (triazolone C-3), 134.8–125.4, 118.0, 116.2 (Ar), 76.7, 73.5, 72.6, 70.3, 69.3 (C-1' – C-5'), 63.1 (C-6'). ESI-MS positive mode (*m/z*): calcd for C₄₆H₃₆N₃O₁₀⁺ [M + H]⁺: 790.2. Found: 790.4.

3.16. 3-(β-D-Glucopyranosyl)-1-(2-naphthyl)-1H-1,2,4-triazol-5(4H)-one (30)

Prepared from compound **29** (0.12 g, 0.15 mmol) according to the general procedure (Section 3.2). Reaction time: 4 h. Purified by column chromatography (85:15 CHCl₃-MeOH) to yield 48 mg (84%) colourless syrup. *R*_f: 0.43 (7:2 CHCl₃-MeOH), [α]_D = +33 (c 0.13, MeOH); ¹H NMR (DMSO-d₆ + 1 drop D₂O) δ (ppm): 8.31 (1H, s, Ar), 8.04–7.88, 7.54–7.45 (6H, m, Ar), 4.10 (1H, d, *J* = 9.4 Hz, H-1'), 3.69 (1H, dd, *J* = 11.7, 2.3 Hz, H-6'a), 3.50 (1H, pseudo t, *J* = 9.4, 9.4 Hz, H-2' or H-3' or H-4'), 3.47 (1H, dd, *J* = 11.7, 5.5 Hz, H-6'b), 3.34–3.29 (2H, m, H-2' or H-3' or H-4', H-5'), 3.21 (1H, pseudo t, *J* = 9.4, 9.4 Hz, H-2' or H-3' or H-4'); ¹³C NMR (DMSO-d₆) δ (ppm): 152.7 (triazolone C=O), 145.9 (triazolone C-3), 135.3, 133.0, 130.3, 128.9, 127.8, 127.6, 127.5, 127.4, 117.6, 114.5 (Ar), 81.4, 77.4, 74.6, 71.1, 69.8 (C-1' – C-5'), 61.0 (C-6'). MS-ESI (*m/z*): Calcd. for C₁₈H₂₀N₃O₆⁺ [M + H]⁺: 374.1. Found: 374.3. Anal: Calcd for C₁₈H₁₉N₃O₆ (M 373.36): C, 57.90; H, 5.13; N, 11.25. Found: C, 57.83; H, 5.31; N, 11.39.

Acknowledgements

This work was supported by the Hungarian Scientific Research Fund (OTKA PD105808). The authors thank K. E. Kövér and I. Timári for recording the ROESY spectra and A. Kiss for the MS measurements.

Supplementary material

Supplementary data to this article can be found online at doi:10.1016/j.carres.2015.12.005.

References

- 588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
1. Henke BR. *RSC Drug Discov Ser* 2012;**27**:324–65.
 2. Sun H, Xu L. *Mini Rev Med Chem* 2010;**10**:1188–93.
 3. Guan T, Qian YS, Tang XZ, Huang MH, Huang LF, Li YM, et al. *J Neurosci Res* 2011;**89**:1829–39.
 4. Tracey WR, Treadway JL, Magee WP, Sutt JC, McPherson RK, Levy CB, et al. *Am J Physiol Heart Circ Physiol* 2004;**286**:H1177–84.
 5. Treadway JL, Magee WP, Hoover DJ, McPherson RK, Martin WH, Zavadski WJ, et al. *Diabetes* 2000;**49**:A127.
 6. Favaro E, Bensaad K, Chong MG, Tennant DA, Ferguson DJP, Snell C, et al. *Cell Metab* 2012;**16**:751–64.
 7. Zois CE, Favaro E, Harris AL. *Biochem Pharmacol* 2014;**92**:3–11.
 8. Somsák L, Czifrák K, Tóth M, Bokor É, Chrysina ED, Alexacou KM, et al. *Curr Med Chem* 2008;**15**:2933–83.
 9. Hayes J, Kantsadi A, Leonidas D. *Phytochem Rev* 2014;**13**:471–98.
 10. Praly JP, Vidal S. *Mini Rev Med Chem* 2010;**10**:1102–26.
 11. Somsák L. *Compt Rend Chimie* 2011;**14**:211–23.
 12. Hadady Z, Tóth M, Somsák L. *Arkivoc* 2004;**vii**:140–9.
 13. Chrysina ED, Kosmopolou MN, Tiraidis C, Kardarakis R, Bischler N, Leonidas DD, et al. *Protein Sci* 2005;**14**:873–88.
 14. Bokor É, Szilágyi E, Docsa T, Gergely P, Somsák L. *Carbohydr Res* 2013;**381**:179–86.
 15. Benltifa M, Vidal S, Fenet B, Msaddek M, Goekjian PG, Praly J-P, et al. *Eur J Org Chem* 2006;4242–56.
 16. Tóth M, Kun S, Bokor É, Benltifa M, Tallec G, Vidal S, et al. *Bioorg Med Chem* 2009;**17**:4773–85.
 17. Bokor É, Docsa T, Gergely P, Somsák L. *ACS Med Chem Lett* 2013;**4**:612–5.
 18. Kun S, Bokor É, Varga G, Szöcs B, Páhi A, Czifrák K, et al. *Eur J Med Chem* 2014;**76**:567–79.
 19. Bokor É, Kun S, Docsa T, Gergely P, Somsák L. *ACS Med Chem Lett* 2015;doi:10.1021/acsmchemlett.5b00361.
 20. Begum J, Varga G, Docsa T, Gergely P, Hayes JM, Juhász L, et al. *Med Chem Comm* 2015;**6**:80–9.
 21. Polya JB. in Potts KT, editor. *Comprehensive heterocyclic chemistry*. Exeter: Pergamon; 1984. p. 733–90.
 22. Weidinger H, Kranz J. *Chem Ber* 1963;**96**:1064–70.
 23. Davoodnia A, Bakavoli M, Soleimany M, Behmadi H. *Chin Chem Lett* 2008;**19**:685–8.
 24. Dowell RI, Hales NH, Tucker H. *Eur J Med Chem* 1993;**28**:513–6.
 25. Mano M, Seo T, Matsuno T, Imai KI. *Chem Pharm Bull* 1976;**24**:2871–6.
 26. Chouaieb H, Ben Mosbah M, Kossentini M, Salem M. *Synth Commun* 2003;**33**:3861–8.
 27. Milcent R, Nguyen TH. *J Heterocycl Chem* 1986;**23**:881–3.
 28. Poonian MS, Nowoswiat EF. *J Org Chem* 1980;**45**:203–8.
 29. Bokor É, Fekete A, Varga G, Szöcs B, Czifrák K, Komáromi I, et al. *Tetrahedron* 2013;**69**:10391–404.
 30. Somsák L, Nagy V. *Tetrahedron Asymmetry* 2000;**11**:1719–27, Corrigendum 2247.
 31. Misra AK, Bokor É, Kun S, Bolyog-Nagy E, Kathó Á, Joó F, et al. *Tetrahedron Lett* 2015;**56**:5995–8.
 32. Speziale AJ, Smith LR, Fedder JE. *J Org Chem* 1965;**30**:4306–7.
 33. Deng JZ, Burgey CS. *Tetrahedron Lett* 2005;**46**:7993–6.
 34. Tsuge O, Hatta T, Mizuguchi R. *Heterocycles* 1994;**38**:235–41.
 35. Rao KS, Wu T-S. *Tetrahedron* 2012;**68**:7735–54.
 36. Ósz E, Somsák L, Szilágyi L, Kovács L, Docsa T, Tóth B, et al. *Bioorg Med Chem Lett* 1999;**9**:1385–90.
 37. Cer RZ, Mudunuri U, Stephens R, Lebeda FJ. *Nucleic Acids Res* 2009;**37**:W441–5.
 38. Kun S, Nagy GZ, Tóth M, Czece L, Nguyen van Nhien A, Docsa T, et al. *Carbohydr Res* 2011;**346**:1427–38.
 39. Feuillastre S, Chajstamatiou AS, Potamitis C, Zervou M, Zoumpoulakis P, Chrysina ED, et al. *Bioorg Med Chem* 2012;**20**:5592–9.
 40. Goyard D, Docsa T, Gergely P, Praly J-P, Vidal S. *Carbohydr Res* 2015;**402**:245–51.
 41. Graham MA, Bethel PA, Burgess J, Fairley G, Glossop SC, Greenwood RDR, et al. *Org Lett* 2013;**15**:6078–81.
- 620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652